Cladribine tablets occupy a distinctive position in the therapeutic arsenal against relapsing multiple sclerosis. The drug is classified as an immune reconstitution therapy, a category of treatments that work not by continuously suppressing the immune system but by delivering short, intense courses of immunomodulation followed by long stretches without active treatment. Administered as two brief annual courses at treatment initiation and again the following year, cladribine selectively targets lymphocytes, the immune cells that drive the inflammatory attacks on myelin at the heart of the disease. Because the drug preferentially depletes memory B cell subsets—populations now understood to be central players in driving relapsing disease—the immune benefit persists long after the tablets themselves have been stopped. Clinical trial data and long-term follow-up studies indicate that in patients who respond well, durable disease control can extend for up to 11 years, vastly exceeding the narrow window during which the drug was actually given.

This treatment-free remission profile is precisely what makes the post-year-4 period so complicated. The pivotal CLARITY trial and its randomized extension established the safety and efficacy of the standard two-course regimen, but randomised evidence for what should happen after four years simply does not exist. Regulatory labels provide limited guidance, and in the real world neurologists face an increasingly common scenario: a patient four or more years out from initiation, clinically well, lymphocyte counts recovered or recovering, with no clear indication from trial data about whether to keep monitoring, give an additional course of cladribine, or switch to a different high-efficacy therapy. The result, the French authors argue, is marked variability in long-term management strategies that has more to do with local practice patterns than with any evidence-based rationale.

The new consensus, led by Vito A. G. Ricigliano of the Neurology Unit at GHNE Paris Saclay Hospital and INSERM UMR 1129, together with colleagues from Toulouse, Rouen, Tours, Nimes, Clermont-Ferrand, Lille, Strasbourg and Montpellier, is built on a synthesis of the available real-world and mechanistic data combined with the collective clinical experience of the French centres. Its central proposal is deceptively simple: at the end of the initial four-year period, every patient should be sorted into one of two profiles. The first and by far the larger group consists of patients who remain clinically and radiologically stable—free of relapses, without evidence of new or enlarging lesions on magnetic resonance imaging, and without confirmed disability progression. The second group comprises patients who show evidence of disease reactivation, whether through clinical relapses, new MRI activity, or both.

For stable patients, the experts suggest that two management strategies are defensible. The first is continued monitoring without additional treatment, an approach that leverages the long tail of immune reconstitution and spares patients further drug exposure. The second is delivering an additional course of cladribine, and the deciding factor here is the presence or absence of risk factors associated with a higher likelihood of disease reactivation. The panel emphasises that the assessment of reactivation risk should begin before cladribine is even started, because certain baseline characteristics—such as a high burden of lesions on MRI at initiation, particularly in the spinal cord and infratentorial regions, younger age at onset of highly active disease, and markers of ongoing inflammatory activity—predict which patients are more likely to break through later. Patients with a high-risk baseline may warrant a lower threshold for additional treatment even while they appear stable, whereas those with a low-risk profile and sustained quiescence can be monitored expectantly. Emerging biomarkers are also factored into this calculus: serum neurofilament light chain, a marker of axonal injury released into the bloodstream when neurons are damaged, and the status of cerebrospinal fluid oligoclonal bands are increasingly being used to gauge whether subclinical disease activity is smouldering beneath an apparently calm clinical surface.

For patients in whom the disease has clearly reactivated, the algorithm turns on the severity of the inflammatory rebound. In cases of milder reactivation, an additional course of cladribine tablets can be considered, effectively repeating the immune reconstitution cycle. The rationale draws on mechanistic studies showing that re-treatment reshapes the memory B cell repertoire again, and on emerging real-world data from Germany—where the CLIP-5 study and longitudinal prescription analyses have tracked patients continuing cladribine beyond year 4—that suggest additional courses can be delivered with acceptable safety under appropriate monitoring, particularly of lymphocyte counts. In cases of more severe inflammatory reactivation, the experts recommend transitioning to an alternative high-efficacy therapy, with the sequencing considerations that entails, including washout periods and the particular hazards of switching directly between certain immunotherapies, such as the known risk of rebound activity after discontinuing fingolimod.

The timing of the publication reflects a genuine inflection point for the cladribine treatment paradigm. The drug’s oral convenience and short dosing schedule have made it increasingly attractive as a first-line high-efficacy option, particularly as the field moves toward early aggressive treatment of multiple sclerosis rather than the older escalation model of reserving potent drugs until milder therapies fail. Delphi consensus panels from Europe and the United States have in recent years endorsed early use of high-efficacy disease-modifying therapies on the grounds that early suppression of inflammatory activity reduces long-term disability accumulation, a principle reinforced by studies showing that much of the disability worsening seen under modern treatment occurs independently of relapses—a phenomenon known as progression independent of relapse activity, or PIRA. Cladribine’s low four-year PIRA rates in pooled analyses of the CLARIFY-MS and MAGNIFY-MS studies have strengthened its position, but every year that passes, the cohort of patients reaching the four-year mark and beyond grows larger, and the absence of trial data becomes more consequential.

The French algorithm is not the first attempt to address the problem—German, Italian, Israeli and southeast European expert groups have issued their own position statements on post-year-4 management, and an earlier French expert opinion published in 2024 addressed holistic long-term care more broadly—but the new paper offers one of the most structured frameworks to date, explicitly built around the two-profile classification and the reactivation-risk stratification that should be set in motion at treatment initiation. The authors are careful to frame their proposal as pragmatic rather than definitive, acknowledging that their algorithm is grounded in currently available data and collective experience rather than the randomised evidence that would ideally guide practice. They call for prospective data collection to refine the approach, and real-world cohorts in Germany, Italy and elsewhere are already generating the kind of longitudinal prescription and outcome data that could eventually validate or revise these recommendations.

For clinicians, the practical message is that the four-year mark should be treated not as an endpoint but as a structured decision point. Every patient approaching that milestone should undergo a thorough clinical assessment, a brain and spinal cord MRI, and ideally biomarker evaluation, and the findings should be interpreted in light of the risk profile established before treatment began. For stable, low-risk patients, watchful waiting may allow years of additional treatment-free remission—the very promise that made immune reconstitution therapy appealing in the first place. For stable but high-risk patients, a proactive additional course may head off a future breakthrough before it occurs. And for patients with overt reactivation, the severity of the rebound should determine whether the immune system is reset once more with cladribine or handed over to a different high-efficacy agent.

The broader significance of the work lies in what it says about the evolving philosophy of multiple sclerosis treatment. A generation ago, the goal was modest symptom suppression with injectable therapies; today, the ambition is durable, mechanistically informed remission with the minimum cumulative drug exposure, guided by biomarkers, imaging and individual risk stratification. Cladribine’s short-course, long-remission profile embodies that philosophy, and the French panel’s algorithm represents an attempt to extend the logic of personalised, evidence-informed decision-making into the one region of the treatment course where the randomised evidence ends and clinical judgment must take over. As the treated population ages into the fifth, sixth and beyond years of therapy, frameworks like this one—transparent, reproducible and explicit about their limitations—may prove as important to outcomes as any single trial result.